Advertisement

Intensity-Modulated Radiotherapy as Primary Therapy for Prostate Cancer: Report on Acute Toxicity After Dose Escalation With Simultaneous Integrated Boost to Intraprostatic Lesion

      Purpose

      To report on the acute toxicity of a third escalation level using intensity-modulated radiotherapy for prostate cancer (PCa) and the acute toxicity resulting from delivery of a simultaneous integrated boost (SIB) to an intraprostatic lesion (IPL) detected on magnetic resonance imaging (MRI), with or without spectroscopy.

      Methods and Materials

      Between January 2002 and March 2007, we treated 230 patients with intensity-modulated radiotherapy to a third escalation level as primary therapy for prostate cancer. If an IPL (defined by MRI or MRI plus spectroscopy) was present, a SIB was delivered to the IPL. To report on acute toxicity, patients were seen weekly during treatment and 1 and 3 months after treatment. Toxicity was scored using the Radiation Therapy Oncology Group toxicity scale, supplemented by an in-house–developed scoring system.

      Results

      The median dose to the planning target volume was 78 Gy. An IPL was found in 118 patients. The median dose to the MRI-detected IPL and MRI plus spectroscopy-detected IPL was 81 Gy and 82 Gy, respectively. No Grade 3 or 4 acute gastrointestinal toxicity developed. Grade 2 acute gastrointestinal toxicity was present in 26 patients (11%). Grade 3 genitourinary toxicity was present in 15 patients (7%), and 95 patients developed Grade 2 acute genitourinary toxicity (41%). No statistically significant increase was found in Grade 2-3 acute gastrointestinal or genitourinary toxicity after a SIB to an IPL.

      Conclusion

      The results of our study have shown that treatment-induced acute toxicity remains low when intensity-modulated radiotherapy to 80 Gy as primary therapy for prostate cancer is used. In addition, a SIB to an IPL did not increase the severity or incidence of acute toxicity.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pollack A.
        • Zagars G.K.
        • Starkschall G.
        • et al.
        Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
        • Zietman A.L.
        • DeSilvio M.L.
        • Slater J.D.
        • et al.
        Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial.
        JAMA. 2005; 294: 1233-1239
        • Peeters S.T.
        • Heemsbergen W.D.
        • Koper P.C.
        • et al.
        Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
        J Clin Oncol. 2006; 24: 1990-1996
        • Zelefsky M.J.
        • Fuks Z.
        • Hunt M.
        • et al.
        High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116
        • Pollack A.
        • Hanlon A.
        • Horwitz E.
        • et al.
        Prostate cancer radiotherapy dose response: An update of the Fox Chase experience.
        J Urol. 2004; 171: 1132-1136
        • Dearnaley D.P.
        • Sydes M.R.
        • Graham J.D.
        • et al.
        Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RTO1 randomised controlled trial.
        Lancet Oncol. 2007; 8: 475-487
        • Kuban D.
        • Tucker S.
        • Dong L.
        • et al.
        Long-term results of a randomized dose escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2006; 66 ([Abstract]): 15
        • Coen J.J.
        • Zietman A.L.
        • Thakral H.
        • et al.
        Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases.
        J Clin Oncol. 2002; 20: 3199-3205
        • Morgan P.B.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        Radiation dose and late failures in prostate cancer.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1074-1081
        • Jacob R.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
        Cancer. 2004; 100: 538-543
        • De Meerleer G.
        • Vakaet L.
        • Meersschout S.
        • et al.
        Intensity-modulated radiation therapy as primary therapy for prostate cancer: Acute toxicity in 114 patients.
        Int J Radiat Oncol Biol Phys. 2004; 60: 777-787
        • De Meerleer G.O.
        • Fonteyne V.H.
        • Vakaet L.
        • et al.
        Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control.
        Radiother Oncol. 2007; 82: 160-166
        • Fonteyne V.
        • De Neve W.
        • Villeirs G.
        • et al.
        Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
        Radiother Oncol. 2007; 84: 156-163
        • Cellini N.
        • Morganti A.G.
        • Mattiucci G.C.
        • et al.
        Analysis of intraprostatic failures in patients with hormonal therapy and radiotherapy: Implications for conformal radiotherapy planning.
        Int J Radiat Oncol Biol Phys. 2002; 53: 595-599
        • Van Lin E.
        • Futterer J.
        • Heijmink S.
        • et al.
        IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
        Int J Radiat Oncol Biol Phys. 2006; 65: 291-303
        • Xia P.
        • Pickett B.
        • Vigneault E.
        • et al.
        Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy.
        Int J Radiat Oncol Biol Phys. 2001; 51: 244-254
        • De Meerleer G.
        • Villeirs G.
        • Bral S.
        • et al.
        The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy.
        Radiother Oncol. 2005; 75: 325-333
        • American Joint Committee on Cancer
        AJCC cancer staging manual.
        5th ed. JB Lippincott, Philadelphia1997
        • Bolla M.
        • Gonzales D.
        • Warde P.
        • et al.
        Improved survival in patients with locally advanced prostate cancer and goserelin.
        N Engl J Med. 1997; 337: 295-300
        • Gottschalk A.R.
        • Roach M.
        The use of hormonal therapy with radiation therapy for prostate cancer: Analysis of prospective randomized trials.
        Br J Cancer. 2004; 90: 950-954
        • Villeirs G.
        • De Meerleer G.
        • Verstraete K.
        • et al.
        Magnetic resonance assessment of prostate localization variability in intensity-modulated radiotherapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1611-1621
        • Cruz M.
        • Tsuda K.
        • Narumi Y.
        • et al.
        Characterization of low-intensity lesions in the peripheral zone of the prostate on pre-biopsy endorectal coil imaging.
        Eur Radiol. 2002; 12: 357-365
        • Scheenen T.W.J.
        • Klomp D.W.J.
        • Rőll S.A.
        • et al.
        Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate.
        Magn Reson Med. 2004; 52: 80-88
        • Yuen J.S.P.
        • Thang C.H.
        • Tan P.H.
        • et al.
        Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy.
        J Urol. 2004; 171: 1482-1486
        • Chen M.
        • Hricak H.
        • Kalbhen C.L.
        • et al.
        Hormonal ablation of prostatic cancer: Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging.
        AJR Am J Roenterol. 1996; 166: 1157-1163
        • De Meerleer G.
        • Villeirs G.
        • Vakaet L.
        • et al.
        The incidence of the inclusion of the sigmoid colon and small bowel in the planning target volume in radiation therapy for prostate cancer.
        Strahlenther Oncol. 2004; 180: 573-581
        • De Gersem W.
        • Claus F.
        • De Wagter C.
        • et al.
        An anatomy-based beam segmentation tool for intensity-modulated radiation therapy and its application to head-and neck cancer.
        Int J Radiat Oncol Biol Phys. 2001; 51: 849-859
        • De Meerleer G.
        • Vakaet L.
        • De Gersem W.
        • et al.
        Radiation therapy of prostate cancer with or without intensity modulated beams: A planning comparison.
        Int J Radiat Oncol Biol Phys. 2000; 47: 639-648
        • De Meerleer G.
        • Vakaet L.
        • De Gersem W.
        • et al.
        Direct segment aperture and weight optimization for intensity-modulated radiation therapy for prostate cancer.
        Strahlenther Oncol. 2004; 180: 136-143
        • Vandecasteele K.
        • De Neve W.
        • Villeirs G.
        • et al.
        Accuracy of ultrasound-guided prostate cancer (UGPP).
        Radiother Oncol. 2004; 73 ([Abstract]): 410
        • Cox J.D.
        • Stelz J.
        • Pajak T.F.
        • et al.
        Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer.
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Hanks G.E.
        • Hanlon A.L.
        • Epstein B.
        • et al.
        Dose response in prostate cancer with 8–12 years' follow-up.
        Int J Radiat Oncol Biol Phys. 2002; 54: 427-435
        • Kupelian P.A.
        • Mohan D.S.
        • Lyons J.
        • et al.
        Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2000; 46: 567-574
        • Zelefsky M.
        • Leibel S.
        • Gaudin P.
        • et al.
        Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 491-500
        • Hoskin P.J.
        • Motohashi K.
        • Bownes P.
        • et al.
        High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomized phase three trial.
        Radiother Oncol. 2007; 84: 114-120
        • Mohan R.
        • Wu Q.
        • Manning M.
        • et al.
        Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers.
        Int J Radiat Oncol Biol Phys. 2000; 46: 619-630
        • Fütterer J.J.
        • Heijmink W.T.
        • Scheenen T.W.
        • et al.
        Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.
        Radiology. 2006; 241: 449-458
        • Speight J.L.
        • Roach M.
        Advances in the treatment of localized prostate cancer: The role of anatomic and functional imaging in men managed with radiotherapy.
        J Clin Oncol. 2007; 25: 987-995
        • Gotten M.
        • Nimrod A.
        Intensity-modulated therapy and inhomogeneous dose to the tumor: A note of caution.
        Int J Radiat Oncol Biol Phys. 1996; 36: 519-522
        • Skwarchuk M.W.
        • Jackson A.
        • Zelefsky M.J.
        • et al.
        Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response.
        Int J Radiat Oncol Biol Phys. 2000; 47: 103-113
        • Kupelian A.P.
        • Reddy C.A.
        • Carlson T.P.
        • et al.
        Preliminary observations on biochemical relapse-free survival after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 53: 904-912
        • Eade T.
        • Hanlon A.
        • Horwitz E.
        • et al.
        What dose of external-beam radiation is high enough for prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2007; 68: 682-689

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.